Key result
CaMKII has emerged as a pro-arrhythmic signaling molecule and potential therapeutic target for arrhythmias and structural heart disease.
This review highlights CaMKII as a pleiotropic pro-arrhythmic signaling molecule and a promising therapeutic target for arrhythmias and structural heart disease.
Answers are grounded in this paper and cite their sources.
Should not yet change arrhythmia management; leaves open CaMKII inhibition as a hypothesis-generating target for future trials.
The multifunctional Ca(2+) calmodulin-dependent protein kinase II (CaMKII) has emerged as a pro-arrhythmic signaling molecule. CaMKII can participate in arrhythmia signaling by effects on ion channel proteins, intracellular Ca(2+) uptake and release, regulation of cell death, and by activation of hypertrophic signaling pathways. The pleuripotent nature of CaMKII is reminiscent of another serine-threonine kinase, protein kinase A (PKA), which shares many of the same protein targets and is the downstream kinase most associated with beta-adrenergic receptor stimulation. The ability of CaMKII to localize and coordinate activity of multiple protein targets linked to Ca(2+) signaling set CaMKII apart from other "traditional" arrhythmia drug targets, such as ion channel proteins. This review will discuss some of the biology of CaMKII and focus on work that has been done on molecular, cellular, and whole animal models that together build a case for CaMKII as a pro-arrhythmic signal and as a potential therapeutic target for arrhythmias and structural heart disease.
No takes yet. Share an insight, caveat, or question.
Mark E. Anderson (2006) conducted a review in Arrhythmias and structural heart disease. CaMKII was evaluated. CaMKII has emerged as a pro-arrhythmic signaling molecule and potential therapeutic target for arrhythmias and structural heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: